VictorManuelVillalobosMDPhD

Oncology • Aurora, CO

Executive Medical Director

Join to view full profile

Dr. Villalobos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Villalobos' full profile

Already have an account?

Office
1665 Aurora Ct
ACP room 5329 Mail stop F704
Aurora, CO 80045
Phone+1 720-848-0467

Fax+1 650-736-8003

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2010 - 2013
Washington University in St. Louis School of MedicineClass of 2008

Certifications & Licensure

CA State Medical License 2009 - Present
CO State Medical License 2015 - 2025

Clinical Trials

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies Start of enrollment: 2018 Mar 14
Active, not recruiting
Phase 1
Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
Available

Publications & Presentations

PubMed

44 citations
Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
Victor M. Villalobos, Francis Hall, Antonio Jimeno, Lia Gore, Kenneth A. Kern
Annals of Surgical Oncology. 2018-03-01
193 citations
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones, Mark Agulnik, Gregory M. Cote
The Lancet. Oncology. 2020-11-01
48 citations
Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report fro...
Lisa M. Kopp, Suman Malempati, Mark Krailo, Yun Gao, Allen Buxton
European Journal of Cancer. 2019-11-01

Lectures

Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

D.C. Week: Less Guessing on Medicare Part D Drug CostsMay 17th, 2019
‘You Saved My Life’: Cancer Survivor to Peyton ManningFebruary 22nd, 2017